Dyshidrotic bullous pemphigoid developing after Moderna mRNA-1273 vaccination

Dyshidrotic bullous pemphigoid developing after Moderna mRNA-1273 vaccination

Bibliographic Details
Main Authors:	Tyng-Shiuan Hsieh, Jau-Shiuh Chen, Tsen-Fang Tsai
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2023-01-01
Series:	Dermatologica Sinica
Online Access:	http://www.dermsinica.org/article.asp?issn=1027-8117;year=2023;volume=41;issue=1;spage=52;epage=53;aulast=Hsieh

Similar Items

Central retinal artery occlusion after Moderna mRNA-1273 vaccination
by: Sin Yu Chow, et al.
Published: (2022-11-01)

New‐onset vitiligo following mRNA‐1273 (Moderna) COVID‐19 vaccination
by: Joshua Kaminetsky, et al.
Published: (2021-09-01)

Bullous pemphigoid in a patient with psoriasis after mRNA COVID‐19 vaccination
by: Arbie Sofia P. Merilleno, et al.
Published: (2023-03-01)

Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review
by: Angel Shabu, et al.
Published: (2023-12-01)

Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination
by: Leelakrishna Channa, BS, et al.
Published: (2021-09-01)

Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination
by: Suresh Babu Chellapandian, et al.
Published: (2022-04-01)

A case of acquired hemophilia A and bullous pemphigoid following SARS-CoV-2 mRNA vaccination
by: Pei-An Fu, et al.
Published: (2022-09-01)

Cutaneous Sarcoidosis-like Eruption Following Second Dose of Moderna mRNA-1273 Vaccine: Case or Relationship?
by: Gerardo Cazzato, et al.
Published: (2023-03-01)

Guillain‐Barré syndrome after mRNA‐1273 (Moderna) COVID‐19 vaccination: A case report
by: Zauraiz Anjum, et al.
Published: (2022-04-01)

Immunogenicity and safety of heterologous mRNA-1273/MVC-COV1901 vaccination versus homologous mRNA1273 vaccination: A randomized, double-blind controlled study
by: Szu-Ting Huang, et al.
Published: (2023-11-01)

Hypersensitivity reactions following the Moderna messenger RNA-1273 vaccine
by: Alex Drohan, MD, et al.
Published: (2021-10-01)

Adult‐onset Still's disease following mRNA‐1273 Moderna COVID‐19 vaccination: A case report
by: Masahiro Iwata, et al.
Published: (2023-04-01)

Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination
by: Oleguer Parés-Badell, et al.
Published: (2022-07-01)

Bullous pemphigoid
by: Denise Miyamoto, et al.

Comparative effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine
by: Nazmul Islam, et al.
Published: (2022-05-01)

Acute Myocarditis Following Vaccination With the First Dose of the mRNA-1273 Vaccine
by: Abdulbaril Olagunju MD, et al.
Published: (2022-04-01)

Profiling antibody epitopes induced by mRNA-1273 vaccination and boosters
by: Bethany Girard, et al.
Published: (2024-03-01)

Myasthenia Gravis Presenting after Administration of the mRNA-1273 Vaccine
by: Yoji Hoshina, et al.
Published: (2022-07-01)

Bullous pemphigoid evolving into cicatricial pemphigoid?
by: Banfield, C, et al.
Published: (1997)

Bullous Pemphigoid and Other Pemphigoid Dermatoses
by: Valeryia Pratasava, et al.
Published: (2021-10-01)

A case of new-onset palmoplantar pustulosis following mRNA COVID-19 vaccination
by: Yun-Shiuan Olivia Hsu, et al.
Published: (2023-01-01)

Impact of Moderna mRNA-1273 Booster Vaccine on Fully Vaccinated High-Risk Chronic Dialysis Patients after Loss of Humoral Response
by: Sammy Patyna, et al.
Published: (2022-04-01)

Antibody response to the messenger RNA‐1273 vaccine (Moderna) in liver transplant recipients
by: Antonio Cuadrado, et al.
Published: (2022-07-01)

Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases
by: Maria De Santis, et al.
Published: (2022-05-01)

Longitudinal extensive transverse myelitis after COVID-19 vaccination (Spikevax mRNA-1273, Moderna) in a patient with rheumatoid arthritis
by: Saemi Choi, et al.
Published: (2022-12-01)

Interventions for bullous pemphigoid.
by: Khumalo, N, et al.
Published: (2005)

Interventions for bullous pemphigoid.
by: Khumalo, N, et al.
Published: (2003)

Induced bullous pemphigoid.
by: Venning, V, et al.
Published: (1995)

Bullous pemphigoid and autoimmunity.
by: Taylor, G, et al.
Published: (1993)

Dyshidrosiform Bullous Pemphigoid
by: Philip R. Cohen
Published: (2021-04-01)

Intraoral bullous pemphigoid
by: Soundarya Sakthıvel, et al.
Published: (2021-06-01)

Erythrodermic bullous pemphigoid
by: Mai Endo, et al.
Published: (2021-01-01)

Cutaneous dermatophytosis mimicking bullous pemphigoid or typical bullous pemphigoid and tinea incognito?
by: Tirado-Sánchez Andrés, et al.
Published: (2019-01-01)

Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine
by: Angel Shabu, et al.
Published: (2023-12-01)

Pityriasis Rosea Shortly After mRNA-1273 COVID-19 Vaccination
by: Sun Hye Shin, et al.
Published: (2022-01-01)

New-onset chilblains in close temporal association to mRNA-1273 vaccination
by: Connie Kha, MD, et al.
Published: (2021-06-01)

Differences in Responses of Immunosuppressed Kidney Transplant Patients to Moderna mRNA-1273 versus Pfizer-BioNTech
by: Dulat Bekbolsynov, et al.
Published: (2024-01-01)

May bullous pemphigoid be worsened by COVID-19 vaccine?
by: Emanuele Cozzani, et al.
Published: (2022-11-01)

Suboptimal humoral immunological response to the 2nd dose of anti-COVID19 mRNA-1273 vaccine (Moderna) in kidney transplant patients
by: Jesús Martín-García, et al.
Published: (2023-05-01)

Immunoglobulin M bullous pemphigoid: An enigma
by: Rosalie Baardman, MD, et al.
Published: (2020-06-01)